Biblio Discovery — Demo Discovery Service

27 hasil untuk "Sean M. Devlin"

Menampilkan 1–20 · 1,66 detik · RSS

  1. Artikel Jurnal Teks lengkap

    Identifying prognostic pairwise relationships among bacterial species in microbiome studies.

    Sean M Devlin; Axel Martin; Irina Ostrovnaya

    PLoS Computational Biology, Vol. 17 No. 11 · 2021 · Inggris · DOAJ Scopus

    In recent literature, the human microbiome has been shown to have a major influence on human health. To investigate this impact, scientists study the composition and abundance of bacterial species, commonly using 16S rRNA gene sequencing, among patients with and without a disease or condition…

    Juga tersedia di: PLOS

  2. Artikel Jurnal Teks lengkap

    Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma

    Even H. Rustad; Malin Hultcrantz; Venkata D. Yellapantula dkk.

    PLOS ONE, Vol. 14 No. 3 · 2019 · Inggris · PLOS Scopus

    Tracking of clonal immunoglobulin V(D)J rearrangement sequences by next generation sequencing is highly sensitive for minimal residual disease in multiple myeloma. However, previous studies have found variable rates of V(D)J sequence identification at baseline, which could limit tracking. Here, we…

    Juga tersedia di: DOAJ

  3. Artikel Jurnal

    HLA-A ∗01:01 Allele Is Associated With Increased Risk of Transplant-Related Mortality After MHC Matched Unmodified Allogeneic Hematopoietic Stem Cell Transplantation

    Emily A. Cowen; Samantha Brown; Rachel E. Reingold dkk.

    Journal of Immunology Research, Vol. 2026 · 2026 · Inggris · DOAJ Scopus

    Acute graft-versus-host disease (aGvHD) remains a substantial cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). Limited studies explore the association between specific major histocompatibility complex (MHC) alleles and aGvHD or transplant-related…

  4. Artikel Jurnal Teks lengkap

    Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

    Kitsada Wudhikarn; Maria Lia Palomba; Martina Pennisi dkk.

    Blood Cancer Journal · 2020 · Inggris · OpenAlex Scopus

    CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell aplasia and hypogammaglobulinemia are common toxicities…

  5. Artikel Jurnal

    Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia

    Mark B. Geyer; Ellen K. Ritchie; Arati V. Rao dkk.

    Haematologica, Vol. 106 No. 8 · 2020 · Inggris · DOAJ Scopus

    Administration of pediatric-inspired chemotherapy to adults up to age 60 with acute lymphoblastic leukemia (ALL) is challenging in part due to toxicities of asparaginase as well as myelosuppression. We conducted a multicenter phase II clinical trial (NCT01920737) investigating a pediatric-inspired…

  6. Artikel Jurnal

    Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

    Tania Jain; Andrea Knežević; Martina Pennisi dkk.

    Blood Advances · 2020 · Inggris · OpenAlex Scopus

    Factors contributing to hematopoietic recovery following chimeric antigen receptor (CAR) T-cell therapy have not been well studied. In an analysis of 83 patients with hematologic malignancies treated with CAR T-cell therapy, we describe patterns of hematopoietic recovery and evaluate potentially…

  7. Artikel Jurnal

    Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition

    Matthew J. Pianko; Sean M. Devlin; Eric R. Littmann dkk.

    Blood Advances, Vol. 3 No. 13 · 2019 · Inggris · DOAJ Scopus

    Abstract: Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity after upfront treatment have superior outcomes compared with those who remain MRD+. Recently, associations have been shown between specific commensal microbes and development of plasma cell…

  8. Artikel Jurnal

    Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma

    Bruno Almeida Costa; Jessica Flynn; Noriko Nishimura dkk.

    Blood Cancer Journal, Vol. 14 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), there is limited data regarding the impact of tocilizumab (TCZ) and corticosteroids (CCS) on chimeric antigen receptor (CAR) T-cell efficacy in…

  9. Artikel Jurnal

    Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

    Alexander P. Boardman; Victoria Gutgarts; Jessica Flynn dkk.

    Haematologica, Vol. 999 No. 1 · 2024 · Inggris · DOAJ Scopus

    Chimeric Antigen Receptor (CAR) T cells targeting CD19 induce durable remissions in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), but many patients experience treatmentrelated toxicity. Cytokine release syndrome and immune effector cell-associated neurologic syndrome are…

  10. Artikel Jurnal

    Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma

    Efrat Luttwak; David Nemirovsky; Sean M. Devlin dkk.

    HemaSphere, Vol. 9 No. 11 · 2025 · Inggris · DOAJ Scopus

    Abstract Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T‐cell therapy, and yet, their dose‐specific impact on outcomes remains uncertain. We retrospectively…

  11. Artikel Jurnal Teks lengkap

    GPRC5D-Targeted CAR T Cells for Myeloma

    Sham Mailankody; Sean M. Devlin; Jonathan Landa dkk.

    New England Journal of Medicine · 2022 · Inggris · OpenAlex Scopus

    BACKGROUND: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patients with advanced myeloma, but relapses are common. G protein-coupled receptor, class C, group 5, member D (GPRC5D) has been identified as an immunotherapeutic…

  12. Artikel Jurnal

    Unified classification and risk-stratification in Acute Myeloid Leukemia

    Yanis Tazi; Juan E. Arango-Ossa; Yangyu Zhou dkk.

    Nature Communications, Vol. 13 No. 1 · 2022 · Inggris · DOAJ Scopus

    Classification and risk-stratification for Acute Myeloid Leukemia (AML) at diagnosis are primarily based on cytogenetics and only a few gene mutations. Here, the authors study the genomic landscape of 3653 AML patients and characterize 16 non-overlapping molecular subgroups of clinical relevance…

  13. Artikel Jurnal

    CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma

    Alejandro Luna; Sean M. Devlin; Kai Rejeski dkk.

    Blood Cancer Journal, Vol. 15 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract The role of extranodal (EN) sites as potential sanctuary regions resistant to CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy in large B-cell lymphoma (LBCL) remains unclear. To investigate this, we retrospectively analyzed 283 adults treated with commercial CD19 CAR-T…

  14. Artikel Jurnal

    Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma : a multi-center propensity score-matched analysis

    Ronit Marcus; Abraham Avigdor; Uri Greenbaum dkk.

    Haematologica, Vol. 999 No. 1 · 2025 · Inggris · DOAJ Scopus

    Locally manufactured chimeric antigen receptor T-cell (CAR T) therapy enables rapid manufacturing and a substantially shorter vein-to-vein time. However, its clinical efficacy compared to commercial CAR T products remains unclear. This retrospective study compared outcomes in patients with Large…

  15. Artikel Jurnal

    Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma

    Ohad Benjamini; Shalev Fried; Roni Shouval dkk.

    Haematologica, Vol. 999 No. 1 · 2024 · Inggris · DOAJ Scopus

    The activity of anti-CD19 CAR T cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and efficacy of CAR T cell therapy in patients with RT…

  16. Artikel Jurnal

    Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma

    Doris Leithner; Jessica R. Flynn; Sean M. Devlin dkk.

    Journal of Hematology & Oncology, Vol. 17 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Relapse and toxicity limit the effectiveness of chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL), yet biomarkers that predict outcomes and toxicity are lacking. We examined radiomic features extracted from pre-CAR-T 18F-fluorodeoxyglucose positron emission…

  17. Artikel Jurnal

    Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia

    Wenbin Xiao; Aaron D. Goldberg; Christopher A. Famulare dkk.

    Haematologica, Vol. 104 No. 7 · 2019 · Inggris · DOAJ Scopus

    Measurable residual disease is associated with inferior outcomes in patients with acute myeloid leukemia (AML). Measurable residual disease monitoring enhances risk stratification and may guide therapeutic intervention. The European LeukemiaNet working party recently came to a consensus…